Definitive Healthcare Corp. (NASDAQ:DH) Given Consensus Recommendation of “Hold” by Brokerages

Shares of Definitive Healthcare Corp. (NASDAQ:DH) have been given an average rating of “Hold” by the twelve analysts that are covering the firm, MarketBeat.com reports. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and three have given a buy rating to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $5.35.

A number of analysts have recently issued reports on the stock. Needham & Company LLC reiterated a “hold” rating on shares of Definitive Healthcare in a report on Thursday, January 16th. Barclays lowered their price target on Definitive Healthcare from $4.00 to $3.00 and set an “underweight” rating on the stock in a research report on Monday, March 3rd. The Goldman Sachs Group reduced their target price on Definitive Healthcare from $4.50 to $3.00 and set a “neutral” rating for the company in a research note on Tuesday, March 4th. Finally, Stephens initiated coverage on Definitive Healthcare in a report on Friday, December 20th. They set an “equal weight” rating and a $5.00 price target for the company.

Definitive Healthcare Price Performance

Shares of Definitive Healthcare stock opened at $2.51 on Tuesday. The company has a market capitalization of $283.41 million, a P/E ratio of -0.81, a price-to-earnings-growth ratio of 4.06 and a beta of 1.48. The company has a debt-to-equity ratio of 0.33, a current ratio of 2.49 and a quick ratio of 2.49. The business has a 50-day moving average of $3.86 and a two-hundred day moving average of $4.18. Definitive Healthcare has a 1 year low of $2.32 and a 1 year high of $8.02.

Definitive Healthcare (NASDAQ:DH) last posted its earnings results on Thursday, February 27th. The company reported $0.03 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.04). Definitive Healthcare had a positive return on equity of 1.76% and a negative net margin of 142.38%. The business had revenue of $62.29 million for the quarter, compared to the consensus estimate of $60.60 million. As a group, equities analysts predict that Definitive Healthcare will post 0.16 EPS for the current year.

Institutional Trading of Definitive Healthcare

Hedge funds and other institutional investors have recently bought and sold shares of the business. Irenic Capital Management LP raised its holdings in Definitive Healthcare by 9.2% in the 4th quarter. Irenic Capital Management LP now owns 7,003,194 shares of the company’s stock valued at $28,783,000 after acquiring an additional 590,009 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in Definitive Healthcare by 1.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,863,912 shares of the company’s stock valued at $7,661,000 after purchasing an additional 23,410 shares in the last quarter. State Street Corp lifted its position in Definitive Healthcare by 29.4% during the third quarter. State Street Corp now owns 1,399,729 shares of the company’s stock worth $6,257,000 after purchasing an additional 317,952 shares during the period. Geode Capital Management LLC grew its stake in Definitive Healthcare by 3.2% during the fourth quarter. Geode Capital Management LLC now owns 1,272,660 shares of the company’s stock worth $5,231,000 after buying an additional 39,938 shares in the last quarter. Finally, 272 Capital LP increased its holdings in Definitive Healthcare by 74.8% in the 3rd quarter. 272 Capital LP now owns 1,114,080 shares of the company’s stock valued at $4,980,000 after buying an additional 476,766 shares during the period. Institutional investors and hedge funds own 98.67% of the company’s stock.

Definitive Healthcare Company Profile

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.